New Australian biosimilar guidance takes up WHO naming proposal
This article was originally published in SRA
Executive Summary
Generics companies planning to market biosimilar medicines in Australia will have to apply to the World Health Organization for a unique INN identifying code, and all biosimilars will have to have a clearly distinguishable trade name, according to guidance just published by the Therapeutic Goods Administration1,2.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.